For research use only, not for therapeutic use.
Zotatifin（Cat No.:I015420）is a novel small molecule designed to target the stress response pathway in cancer cells, particularly by inhibiting the heat shock protein 70 (HSP70). By disrupting the function of HSP70, zotatifin promotes the degradation of oncogenic proteins, thereby inhibiting tumor growth. It has shown efficacy in preclinical models of various cancers, including lung and breast cancers. Zotatifin’s unique mechanism of action suggests potential synergy with other cancer therapies. Ongoing clinical trials aim to evaluate its safety, tolerability, and overall effectiveness in patients with advanced malignancies.
| Catalog Number | I015420 |
| CAS Number | 2098191-53-6 |
| Molecular Formula | C₂₈H₂₉N₃O₅ |
| Purity | ≥95% |
| IUPAC Name | 4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile |
| InChI | InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1 |
| InChIKey | QYCXWOACFWMQFO-WZWZCULESA-N |
| SMILES | CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5 |
| Reference | [1]. Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.<br>[2]. Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature. 2020 Apr 30. |
